Valneva (NASDAQ:VALN – Get Free Report) and BioCardia (NASDAQ:BCDA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
Analyst Ratings
This is a summary of current recommendations and price targets for Valneva and BioCardia, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valneva | 0 | 0 | 3 | 0 | 3.00 |
| BioCardia | 0 | 1 | 1 | 0 | 2.50 |
Valneva currently has a consensus target price of $21.67, suggesting a potential upside of 183.60%. BioCardia has a consensus target price of $4.00, suggesting a potential upside of 962.13%. Given BioCardia’s higher possible upside, analysts plainly believe BioCardia is more favorable than Valneva.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Valneva | -65.99% | -59.48% | -19.17% |
| BioCardia | -2,425.79% | -3,638.68% | -228.55% |
Insider & Institutional Ownership
11.4% of Valneva shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 23.9% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Valneva has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.
Valuation and Earnings
This table compares Valneva and BioCardia’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valneva | $165.52 million | 3.21 | -$109.78 million | ($1.58) | -4.84 |
| BioCardia | $480,000.00 | 21.08 | -$11.57 million | ($0.55) | -0.68 |
BioCardia has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Summary
Valneva beats BioCardia on 7 of the 13 factors compared between the two stocks.
About Valneva
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
